Takeda Pharmaceutical Co Ltd (NYSE:TAK) shares are down on Friday morning as the company is reportedly demonstrating positive Phase 3 data for its drug Entyvio.

This news comes as the broader market experienced mixed performance, with the S&P 500 and Nasdaq both showing slight gains while the Dow Jones declined.

• What’s next for TAK stock?

Takeda’s recent announcement highlights the potential of Entyvio (vedolizumab) to address treatment gaps for patients with ulcerative colitis and Crohn’s disease.

Trial Data

Takeda released positive data from the pivotal Phase 3 KEPLER trial of Entyvio (vedolizumab) for patients aged between two and 17 years with moderately to severely active ulcerative colitis, a chronic inflammatory disease of the gastrointestinal tract.

The company reported that the drug demonstrated significant ...